175 related articles for article (PubMed ID: 36293051)
1. Anti-PTK7 Monoclonal Antibodies Exhibit Anti-Tumor Activity at the Cellular Level and in Mouse Xenograft Models of Esophageal Squamous Cell Carcinoma.
Kim JH; Shin WS; Lee SR; Kim S; Choi SY; Lee ST
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293051
[TBL] [Abstract][Full Text] [Related]
2. PTK7, a Catalytically Inactive Receptor Tyrosine Kinase, Increases Oncogenic Phenotypes in Xenograft Tumors of Esophageal Squamous Cell Carcinoma KYSE-30 Cells.
Shin WS; Park MK; Kim JH; Oh SW; Jang JY; Lee H; Lee ST
Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216506
[TBL] [Abstract][Full Text] [Related]
3. Catalytically defective receptor protein tyrosine kinase PTK7 enhances invasive phenotype by inducing MMP-9 through activation of AP-1 and NF-κB in esophageal squamous cell carcinoma cells.
Shin WS; Hong Y; Lee HW; Lee ST
Oncotarget; 2016 Nov; 7(45):73242-73256. PubMed ID: 27689325
[TBL] [Abstract][Full Text] [Related]
4. Oncogenic role of protein tyrosine kinase 7 in esophageal squamous cell carcinoma.
Shin WS; Kwon J; Lee HW; Kang MC; Na HW; Lee ST; Park JH
Cancer Sci; 2013 Aug; 104(8):1120-6. PubMed ID: 23663482
[TBL] [Abstract][Full Text] [Related]
5. Biphasic regulation of tumorigenesis by PTK7 expression level in esophageal squamous cell carcinoma.
Shin WS; Gim J; Won S; Lee ST
Sci Rep; 2018 Jun; 8(1):8519. PubMed ID: 29867084
[TBL] [Abstract][Full Text] [Related]
6. Catalytically inactive receptor tyrosine kinase PTK7 activates FGFR1 independent of FGF.
Shin WS; Lee HW; Lee ST
FASEB J; 2019 Nov; 33(11):12960-12971. PubMed ID: 31490704
[TBL] [Abstract][Full Text] [Related]
7. PTK7 is a novel oncogenic target for esophageal squamous cell carcinoma.
Liu K; Song G; Zhang X; Li Q; Zhao Y; Zhou Y; Xiong R; Hu X; Tang Z; Feng G
World J Surg Oncol; 2017 May; 15(1):105. PubMed ID: 28545451
[TBL] [Abstract][Full Text] [Related]
8. PTK7 regulates radioresistance through nuclear factor-kappa B in esophageal squamous cell carcinoma.
Park M; Yoon HJ; Kang MC; Kwon J; Lee HW
Tumour Biol; 2016 Oct; 37(10):14217-14224. PubMed ID: 27557627
[TBL] [Abstract][Full Text] [Related]
9. PTK7 promotes the malignant properties of cancer stem-like cells in esophageal squamous cell lines.
Bie J; Hu X; Yang M; Shi X; Zhang X; Wang Z
Hum Cell; 2020 Apr; 33(2):356-365. PubMed ID: 31894477
[TBL] [Abstract][Full Text] [Related]
10. [The inhibition effects of apatinib on cell proliferation, migration and apoptosis in esophageal carcinoma via Ras/Raf/MEK/ERK and JAK2/STAT3 pathways].
Feng Y; Zhou MY; Sun F; Kong Z; Wang J; Sun ZQ; Hu LJ; Wang JL; Hua Q; Yu JP
Zhonghua Zhong Liu Za Zhi; 2019 Apr; 41(4):263-275. PubMed ID: 31014051
[No Abstract] [Full Text] [Related]
11. Bit1 knockdown contributes to growth suppression as well as the decreases of migration and invasion abilities in esophageal squamous cell carcinoma via suppressing FAK-paxillin pathway.
Fan T; Chen J; Zhang L; Gao P; Hui Y; Xu P; Zhang X; Liu H
Mol Cancer; 2016 Mar; 15():23. PubMed ID: 26956728
[TBL] [Abstract][Full Text] [Related]
12. Metformin Inhibited Growth, Invasion and Metastasis of Esophageal Squamous Cell Carcinoma in Vitro and in Vivo.
Liang F; Wang YG; Wang C
Cell Physiol Biochem; 2018; 51(3):1276-1286. PubMed ID: 30481793
[TBL] [Abstract][Full Text] [Related]
13. Knockdown of PTK7 Reduces the Oncogenic Potential of Breast Cancer Cells by Impeding Receptor Tyrosine Kinase Signaling.
Shin WS; Oh SW; Park HN; Kim JH; Lee ST
Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569547
[TBL] [Abstract][Full Text] [Related]
14. A novel Fc-enhanced humanized monoclonal antibody targeting B7-H3 suppresses the growth of ESCC.
Wu H; Liu C; Yuan Q; Qiao Y; Ding Y; Duan L; Li W; Zhang M; Zhang X; Jiang Y; Lu J; Dong Z; Wang T; Liu K; Zhao J
Oncoimmunology; 2023; 12(1):2282250. PubMed ID: 38126034
[TBL] [Abstract][Full Text] [Related]
15. Anti-cancer Effects of a Novel Quinoline Derivative 83b1 on Human Esophageal Squamous Cell Carcinoma through Down-Regulation of COX-2 mRNA and PGE
Pun IH; Chan D; Chan SH; Chung PY; Zhou YY; Law S; Lam AK; Chui CH; Chan AS; Lam KH; Tang JC
Cancer Res Treat; 2017 Jan; 49(1):219-229. PubMed ID: 27456944
[TBL] [Abstract][Full Text] [Related]
16. CDK11
Du Y; Yan D; Yuan Y; Xu J; Wang S; Yang Z; Cheng W; Tian X; Kan Q
Cell Cycle; 2019 Feb; 18(4):452-466. PubMed ID: 30722725
[TBL] [Abstract][Full Text] [Related]
17. Nuclear Localization of DNAJB6 Is Associated With Survival of Patients With Esophageal Cancer and Reduces AKT Signaling and Proliferation of Cancer Cells.
Yu VZ; Wong VC; Dai W; Ko JM; Lam AK; Chan KW; Samant RS; Lung HL; Shuen WH; Law S; Chan YP; Lee NP; Tong DK; Law TT; Lee VH; Lung ML
Gastroenterology; 2015 Dec; 149(7):1825-1836.e5. PubMed ID: 26302489
[TBL] [Abstract][Full Text] [Related]
18. Anti-PTK7 Monoclonal Antibodies Inhibit Angiogenesis by Suppressing PTK7 Function.
Oh SW; Shin WS; Lee ST
Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139622
[TBL] [Abstract][Full Text] [Related]
19. HERG1 promotes esophageal squamous cell carcinoma growth and metastasis through TXNDC5 by activating the PI3K/AKT pathway.
Wang H; Yang X; Guo Y; Shui L; Li S; Bai Y; Liu Y; Zeng M; Xia J
J Exp Clin Cancer Res; 2019 Jul; 38(1):324. PubMed ID: 31331361
[TBL] [Abstract][Full Text] [Related]
20. High expression of Collagen Triple Helix Repeat Containing 1 (CTHRC1) facilitates progression of oesophageal squamous cell carcinoma through MAPK/MEK/ERK/FRA-1 activation.
Wang C; Li Z; Shao F; Yang X; Feng X; Shi S; Gao Y; He J
J Exp Clin Cancer Res; 2017 Jun; 36(1):84. PubMed ID: 28645305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
